Inhibiting MEK in MAPK pathway-activated myeloma

Leukemia

Volumn 30, Issue 4, 2016, Pages 976-980

  Heuck, C J ^a   Jethava, Y ^a   Khan, R ^a   Van Rhee, F ^a   Zangari, M ^a   Chavan, S ^a   Robbins, K ^a   Miller, S E ^a   Matin, A ^a   Mohan, M ^a   Ali, S M ^b   Stephens, P J ^b   Ross, J S ^b,c   Miller, V A ^b   Davies, F ^a   Barlogie, B ^a   Morgan, G ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b FOUNDATION MEDICINE   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARFILZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; MESNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; POMALIDOMIDE; THALIDOMIDE; TRAMETINIB; BETA INTEGRIN; BETA7 INTEGRIN; CCND2 PROTEIN, HUMAN; CCR1 PROTEIN, HUMAN; CHEMOKINE RECEPTOR CCR1; CYCLIN D2; MAP2K1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PROTEIN KINASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; TUMOR MARKER;

ADULT; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CASE REPORT; CHEMOEMBOLIZATION; DRUG MEGADOSE; EXTRAMEDULLARY DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LETTER; LIVER; MALE; MEDICAL HISTORY; MESENTERY LYMPH NODE; MIDDLE AGED; MULTIPLE MYELOMA; PARASPINAL MUSCLE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CANCER STAGING; FOLLOW UP; GENETICS; HIGH THROUGHPUT SEQUENCING; PATHOLOGY; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION;

BIOMARKERS, TUMOR; CYCLIN D2; FOLLOW-UP STUDIES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INTEGRIN BETA CHAINS; MALE; MAP KINASE KINASE 1; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIDONES; PYRIMIDINONES; RECEPTORS, CCR1; RETROSPECTIVE STUDIES;

EID: 84940688572     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.208     Document Type: Letter

References (15)

1. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012; 26: 149-157
2. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471: 467-472
3. Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 2014; 25: 91-101
4. Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 2014; 5: 2997
5. Walker BA, Wardell CP, Melchor L, Brioli A, Johnson DC, Kaiser MF, et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 2014; 28: 384-390
6. Andrulis M, Lehners N, Capper D, Penzel R, Heining C, Huellein J, et al. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov 2013; 3: 862-869
7. Garnett MJ, Rana S, Paterson H, Barford D, Marais R. Wild-Type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell 2005; 20: 963-969
8. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. RAF inhibitors prime wild-Type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464: 431-435
9. Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, Kulkarni SG, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 2011; 17: 989-1000
10. Shaughnessy JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, et al A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109: 2276-2284
11. Durie BGM, Harousseau J-L, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473
12. Annunziata CM, Hernandez L, Davis RE, Zingone A, Lamy L, Lam LT, et al. A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood 2011; 117: 2396-2404
13. Barlogie B, Shaughnessy JD. Early results of total therapy II in multiple myeloma: implications of cytogenetics and FISH. Int J Hematol 2002; 76 (Suppl 1): 337-339
14. Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, et al Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007; 138: 176-185
15. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65